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doi:10.1016/j.jtcvs.2006.01.027bjective: Left ventricular assist device support for patients with chronic heart
ailure can significantly improve -adrenergic receptor signaling, which is likely
ritical to myocardial recovery. The mechanism underlying the restoration of
-adrenergic receptor signaling is unclear. This study investigates our hypothesis
hat restoration of cardiac -adrenergic receptor signaling by left ventricular assist
evices results from inhibition of the G protein–coupled receptor kinase-2, a G
rotein–coupled receptor kinase that specifically phosphorylates and desensitizes
gonist-occupied -adrenergic receptors.
ethods: Left ventricular -adrenergic receptor signaling was assessed in biopsy
pecimens taken from patients with chronic heart failure (n  12) at the time of left
entricular assist device implantation (heart failure group) and again at the time of
eart transplantation (left ventricular assist device group). Signaling was also
tudied in left ventricular biopsy specimens from nonfailing control (n  8) hearts
nonfailing control group). Signaling was assessed by measuring sarcolemmal
embrane -adrenergic receptor density, adenylyl cyclase activity, G protein ex-
ression, and G protein–coupled receptor kinase-2 expression and activity.
esults: Left ventricular -adrenergic receptor signaling was severely decreased in
he heart failure group versus that seen in the nonfailing control group, as demon-
trated by adenylyl cyclase activity. G protein–coupled receptor kinase-2 expression
nd activity was increased 3-fold in the heart failure group versus that seen in the
onfailing control group. After left ventricular assist device support, -adrenergic
eceptor signaling was restored to levels similar to those seen in the nonfailing
ontrol group. G protein–coupled receptor kinase-2 expression and activity were
arkedly diminished after left ventricular assist device support compared with that
een in the heart failure group and were not different from that seen in the nonfailing
ontrol group.
onclusion: In chronic heart failure left ventricular assist device support leads to
estoration of cardiac -adrenergic receptor signaling. The primary mechanism
ppears to be diminished myocardial G protein–coupled receptor kinase-2 activity.
his demonstrates the potentially beneficial effects of G protein–coupled receptor
inase-2 inhibition on -adrenergic receptor signaling in heart failure and might
epresent a novel therapeutic strategy for this disease process.
eft ventricular assist devices (LVADs) have become increasingly important
as a therapeutic option for patients with end-stage heart failure (HF). In
addition to the significant clinical benefits provided by LVADs, many basic
cientific observations have been made regarding several important myocardial
ignaling pathways in HF. LVADs can reverse many of the molecular, cellular, and
eurohormonal abnormalities characteristic of advanced HF.1-6 When the heart fails,
constellation of biochemical defects has been noted that includes significantlterations in the -adrenergic receptor (AR) signaling system. Dysfunctional
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CSPAR signaling in HF includes receptor downregulation and
mpaired signaling through remaining receptors, which is
nown as desensitization.7-9 HF is associated with an in-
reased level of circulating catecholamines and an approx-
mately 3-fold increase in activity of the G protein–coupled
eceptor kinase-2 (GRK2).10,11 GRK2, also known as AR
inase-1 (ARK1), is a member of the GRK family of
erine-threonine kinases and can phosphorylate and desen-
itize agonist-occupied ARs.12 It has recently been shown
hat LVAD support restores AR responsiveness and re-
erses receptor downregulation in failing human hearts.13
owever, the mechanism underlying this restoration of sig-
aling is unclear. In addition to the hemodynamic effects of
echanical unloading, it appears that some aspects of re-
erse remodeling might also depend on normalization of the
eurohormonal milieu.1,14
We hypothesized that the primary mechanism of resto-
ation of left ventricular AR signaling after LVAD support
s a decrease in myocardial GRK2 activity leading to up-
egulation and improved signaling through ARs. GRK2
as been shown to be a critical modulator of cardiac func-
ion in vivo,15,16 and inhibition of GRK2 activity as a result
f LVAD support might play an important role in the
otential recovery of ventricular function in end-stage HF.
aterials and Method
yocardial Tissue Collection
he left ventricular apical core excised during implantation of the
eartMate XVE LVAS (Thoratec) for each patient was snap-
rozen in liquid nitrogen and stored at 80°C. A section of the
nterior wall of the left ventricle was then excised and stored in
dentical fashion after LVAD explantation and cardiectomy at the
ime of heart transplantation. All samples were paired from LVAD
mplantation to transplantation (n  12). Nonfailing control left
entricular apical tissue was obtained from organ donors whose
earts were unsuitable for transplantation but who had normal
Abbreviations and Acronyms
AC  adenylyl cyclase
ANOVA  analysis of variance
ATP  adenosine triphosphate
AR  -adrenergic receptor
ARK1  -adrenergic receptor kinase-1
Bmax  total AR density
cAMP  cyclic adenosine monophosphate
DU  densitometry units
GRK  G protein–coupled receptor kinase
HF  heart failure
LVAD  left ventricular assist device
NF group nonfailing groupentricular function and no structural heart disease (n  8). d
76 The Journal of Thoracic and Cardiovascular Surgery ● Mayrotein Immunoblotting
issue was homogenized in ice-cold lysis buffer (25 mmol/L
ris-HCl [pH 7.5], 5 mmol/L ethylenediamine tetraacetic acid,
mmol/L ethyleneglycol-bis-(-aminoethylether)-N,N,N=,N=-
etraacetic acid, 10 g/mL leupeptin, 20 g/mL aprotinin, and
mmol/L phenylmethylsulfonyl fluoride). Nuclei and tissue
ere separated by means of centrifugation at 800g for 20 min-
tes. The crude supernatant was then centrifuged at 20,000g for 20
inutes. Protein concentrations were determined on the superna-
ant (cytosolic fraction). Sedimented proteins (membrane fraction)
ere resuspended in 50 mmol/L N-2-hydroxyethylpiperazine-N-
-ethanesulfonic acid (pH 7.3) and 5 mmol/L MgCl2. The immu-
odetection of myocardial levels of ARK1 (GRK2, polyclonal
abbit IgG; Santa Cruz Biotechnology, Inc) was performed on an
qual amount of protein from cytosolic and membrane extracts
80 g) electrophoresed through 12% Tris-glycine gels and trans-
erred to nitrocellulose. Membranes were blocked in 5% nonfat
ried milk in 0.1% Tween 20 in phosphate-buffered saline for 1
our at room temperature. The protein was visualized by using a
orseradish peroxidase–linked secondary antibody and ECL de-
ection (Amersham).
easurement of GRK Activity
he membrane fractions of the myocardial extracts were used to
etermine GRK activity. Extracts (100 g of protein) were incubated
ith rhodopsin-enriched rod outer-segment membranes in reaction
uffer containing the following: MgCl2, 10 mmol/L; Tris-HCl, 20
mol/L; ethylenediamine tetraacetic acid, 2 mmol/L; ethyleneglycol-
is-(-aminoethylether)-N,N,N=,N=-tetraacetic acid, 5 mmol/L;
nd adenosine triphosphate (ATP), 0.1 mmol/L (containing
-32P]ATP), as previously described.15 After incubating in white
ight for 15 minutes at room temperature, reactions were quenched
ith ice-cold lysis buffer and centrifuged for 15 minutes at
3,000g. Sedimented proteins were resuspended in 25 L of
rotein gelloading dye and treated with 12% sodium dodecyl-
ulfate polyacrylamide gel electrophoresis. Phosphorylated rho-
opsin was visualized by means of autoradiography of dried poly-
crylamide gels and quantified by using a Molecular Dynamics
hosphorImager.
adioligand Binding Assays
otal AR density (Bmax) was determined by incubating 25 g of
ardiac sarcolemmal membranes with a saturating concentration of
odine 125–labeled cyanopindolol and 20 mol/L alprenolol to
efine nonspecific binding. Sarcolemmal membrane samples were
tudied in triplicate with 80 pmol/L iodine 125–labeled cyanopin-
olol and 104 mol/L isoproterenol in 250 L of binding buffer
50 mmol/L N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
pH 7.3], 5 mmol/L MgCl2, and 0.1 mmol/L ascorbic acid). Assays
ere performed at 37°C for 1 hour and then filtered over GF/C
lass fiber filters (Whatman) that were washed twice and counted
n a gamma counter. Data were analyzed by means of nonlinear
east-square curve fit (GraphPad Prism).
arcolemmal Membrane Adenylyl Cyclase Activity
ardiac sarcolemmal membranes (20 g of protein) were incu-
ated for 15 minutes at 37°C with [-32P]ATP under basal con-
itions, 104 mol/L isoproterenol, or 10 mmol/L NaF. Cyclic
2006
au
S
R
a
w
I
t
a
w
R
P
P
p
L
p
m
i
r
t
i
p
r
d
e
m
h
t
H
N
w
u
M
W
b
L
c
s
t
m
a
c
4
s
u
t
w
2
i
i
s
c
1
a
L
2

c

p
g
c
i
p
c
M
B
b
g
8
w
g
T
G
N
H
L
D
f
v
i
F
a
u
N
N
Pandalai et al Cardiopulmonary Support and Physiology
CS
Pdenosine monophosphate (cAMP) production was quantified by
sing standard methods described previously.17
tatistical Analysis
epeated-measures analysis of variance (ANOVA) was used to
nalyze serial data over time within treatment groups. Analyses
ere conducted with Statview 4.01 software (Abacus Concepts
nc). Experimental groups were compared by using the Student
test or 1-way ANOVA, as appropriate. The Bonferroni test was
pplied to all significant ANOVA results by using SigmaStat soft-
are. All results are expressed as means standard error of the mean.
esults
atient Population
atient demographics are summarized in Table 1. All 12
atients underwent implantation of the HeartMate XVE
VAS during hospitalization for decompensated HF. All
atients were receiving intravenous inotropic support with
ilrinone before LVAD insertion. Six patients were receiv-
ng a -blocker before LVAD implantation. None were
eceiving this therapy after LVAD implantation. Four pa-
ients received intra-aortic balloon pumping before LVAD
mplantation. The indication for LVAD implantation in all
atients was as a bridge to transplantation. No patients
equired inotropic support for right heart dysfunction by 7
ays after LVAD insertion. All patients underwent LVAD
xplantation and orthotopic heart transplantation after a
ean of 6.4  1.8 months of LVAD support. All patients
ad New York Heart Association class IV HF symptoms at
he time of LVAD implantation and improved to New York
eart Association class I by the time of heart transplantation.
ormal left ventricular tissue was harvested from organ donors
hen the heart was not procured, despite satisfactory ventric-
lar function.
yocardial AR Signaling
e assessed AR-effector coupling in sarcolemmal mem-
ranes prepared from left ventricular apical tissue in the HF,
VAD, and nonfailing (NF) groups by measuring adenylyl
yclase (AC) activity (Figure 1). Basal AC activity was
ignificantly lower in the HF group compared with that in
he NF group (32.4  1.4 vs 58.4  2.0 pmol cAMP ·
ABLE 1. Clinical profile for patients in this study
roup M/F Age (y) DCM/ICM Drugs
F (n  8) 4/4 42  4 — Dopamine
F (n  12) 8/4 57  6 5/7 Milrinone, carvedilol
VAD (n  12) 8/4 58 5 5/7 AI
CM, Dilated cardiomyopathy; ICM, ischemic cardiomyopathy; NF, non-
ailing; HF, medically managed chronic heart failure; LVAD, after left
entricular assist device implantation; AI, angiotensin-converting enzyme
nhibitor.g1 · min1, P  .001). Isoproterenol-stimulated AC f
The Journal of Thoracicctivity was also significantly blunted in the HF group
ompared with that in the NF group (55.7  3.0 vs 103.1 
.25 pmol cAMP · mg1 · min1, P  .001), indicating
evere uncoupling of myocardial ARs. AC activity stim-
lated by sodium fluoride, which induces maximal stimula-
ion of the  subunit of the AC-stimulatory G protein, Gs,
as similar in both the HF and NF groups (231.5  22.7 vs
62.5  19.8 pmol cAMP · mg1 · min1, P  .3),
ndicating that the defect in AR signaling in the HF group
s occurring at the receptor-G protein level. After LVAD
upport, there was a significant increase in basal AC activity
ompared with that in the HF group (57.8  1.8 vs 32.4 
.4 pmol cAMP · mg1 · min1, P  .001). There was
lso greater isoproterenol-stimulated AC activation after
VAD support compared with that in the HF group (95.3
.8 vs 55.6 3.0 pmol cAMP · mg1 · min1, P .001).
AR signaling is severely impaired in the chronic HF group
ompared with that seen in the NF control group. Basal and
-agonist–stimulated AC activities were markedly im-
roved after LVAD support compared with those in the HF
roup and not statistically different from those in the NF
ontrol group. These data indicate that mechanical unload-
ng with an LVAD can restore left ventricular AR cou-
ling to AC to a degree that is similar to that seen in NF
ontrol subjects.
yocardial AR Density and G Protein Expression
max was measured in all groups by means of radioligand
inding (Figure 2). Bmax was significantly lower in the HF
roup compared with that in the NF group (41.5  2.0 vs
0.3  1.8 fmol/mg membrane protein, P  .001). Bmax
as increased after LVAD support and was significantly
reater than in the HF group (77.3  2.0 vs 41.5  2.0
igure 1. Myocardial sarcolemmal membrane adenylyl cyclase
ctivity in the nonfailing (NF), heart failure (HF), and left ventric-
lar assist device (LVAD) groups. ISO, 104 mol/L isoproterenol.
F group, n  8; HF and LVAD groups, n  12. *P < .001 versus
F group. #P< .001 versus HF group and P> .40 versus NF group.mol/mg, P  .004). Bmax was similar between the LVAD
and Cardiovascular Surgery ● Volume 131, Number 5 977
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CSPnd NF groups (77.3  2.0 vs 80.3  1.8 fmol/mg, P 
14). LVAD support led to upregulation of total left ven-
ricular AR density, which was not significantly different
rom that seen in the NF control group.
Left ventricular sarcolemmal membrane G protein ex-
ression was also quantified by means of Western analysis.
here was no difference in expression of the AC-stimula-
ory G protein (Gs) among the HF, LVAD, and NF groups
data not shown). Expression of Gi, the AC-inhibitory G
rotein, was significantly increased in the HF group com-
ared with the NF control group (23.8  2.1 vs 10.6  2.8
ensitometry units [DU], P  .001). LVAD support led to
significant decrease in left ventricular membrane Gi
xpression compared with that in the HF group (6.6  3.0
s 23.8 2.1 DU, P .005) and was not different from that
een in the NF control group (Figure 3).
igure 2. Myocardial sarcolemmal membrane -adrenergic re-
eptor (AR) density. Bmax, Total AR density; NF, nonfailing
roup; HF, heart failure group; LVAD, left ventricular assist device
roup. *P < .001 versus NF group. #P < .004 versus HF group and
> .10 versus NF group.
igure 3. Left ventricular protein expression of the adenylyl cy-
lase–inhibitory G protein (Gi). NF, Nonfailing group; HF, heart
ailure group; LVAD, left ventricular assist device group. *P <
001 versus NF group. #P < .005 versus HF group and P > .20gersus NF group.
78 The Journal of Thoracic and Cardiovascular Surgery ● Mayyocardial GRK Expression and Activity
o determine another potential mechanism for the improve-
ent in left ventricular AR functional coupling after
VAD support, we studied the expression and activity of
he primary GRK in the heart, GRK2 (also known as
ARK1). Left ventricular expression of GRK2 was in-
reased 2.5-fold in the HF group compared with the NF
ontrol group (23.9 2.6 vs 7.6 1.6 DU, P .01). GRK2
xpression was significantly lower in the LVAD group
ompared with that in the HF group (10.1  0.88 vs 23.9 
.6 DU, P  .001) and similar to the level of expression in
he NF group (10.1  0.88 vs 7.6  1.6 DU, P  .07;
igure 4, A). GRK2 activity was assessed by using a rho-
opsin phosphorylation assay, and the results were similar
o the expression data (Figure 4, B). GRK2 activity was
ncreased 3-fold in the HF group compared with that in the
igure 4. A, Left ventricular protein expression of G protein–
oupled receptor kinase-2 (GRK2). *P < .01 versus NF group. #P <
001 versus HF group and P> .10 versus NF group. B, Left ventricular
RK2 activity. *P< .004 versus NF group. #P< .005 versus HF group
nd P> .30 versus NF group. NF, Nonfailing group; HF, heart failure
roup; LVAD, left ventricular assist device group.
2006
N
A
l
D
D
T
i
s
t
m
2
p
s
C
d
t
t
t
s
i
a
s
a
t
e
i
G
i
H
t
s
i
c
e
d
t
a
p
a
s
h
m
c
l
i
r
i
m
r
t
d
f
m
m
v
e
m
i
d
a
w
o
t
a
d
a
L
p
n
s
c
w
c
f
c
v
u
p
e
b
i
i
i
w
m
s
d
s
a
H
d
b
a
G
i
s
a
r
Pandalai et al Cardiopulmonary Support and Physiology
CS
PF control group (31.3 1.7 vs 10.9 3.6 DU, P .004).
fter LVAD support, GRK2 activity was decreased to the
evel seen in the NF control group (11.4 3.3 vs 10.9 3.6
U, P  .3).
iscussion
he myocardial AR signaling pathway plays a critical role
n the regulation of cardiac contractility. ARs (1 and 2
ubtypes) are the primary myocardial targets of the sympa-
hetic neurotransmitter norepinephrine and the adrenal hor-
one epinephrine. Activation of ARs in the heart by these
catecholamines leads to positive chronotropic and inotro-
ic action through stimulation of adenylyl cyclase and sub-
equent increases in cAMP and intracellular Ca2 release.9
ontinued exposure of ARs to agonists results in a rapid
ecrease in responsiveness, which is known as desensitiza-
ion.7 Agonist-dependent desensitization can be initiated by
he phosphorylation of activated receptors by members of
he family of GRKs.12 GRK2 (or ARK1) is a GRK that
pecifically phosphorylates activated 1- and 2-ARs, lead-
ng to desensitization in vitro and in vivo.12,15,18
HF in human subjects has been characterized by specific
lterations in the AR signaling system. These include
elective downregulation of 1-ARs by approximately 50%
nd desensitization of the remaining ARs, which leads to
he blunting of further agonist-mediated stimulation.7,19 The
nhanced desensitization of myocardial ARs is likely due,
n large part, to the increased expression and activity of
RK2 (approximately 3-fold) present in human HF.10,11 It
s generally thought that these changes in the AR system in
F are triggered by increased sympathetic stimulation of
he heart in this disease state.20 The dysfunctional AR
ignaling, including increased GRK2 expression and activ-
ty, is a contributing factor to the impaired myocardial
ontractility seen in HF.
LVAD support has been shown to have many beneficial
ffects as a result of mechanical unloading. These include
ecreasing heart size,21,22 improvement in ventricular func-
ion,2 decreased plasma catecholamines1,23 and cytokines,24
nd decreased ventricular expression of atrial natriuretic
eptide25 and tumor necrosis factor .26 Recent studies have
lso demonstrated an improvement in left ventricular AR
ignaling after long-term LVAD support.13,14 These studies
ave shown that LVAD support can lead to upregulation of
yocardial AR density to near normal and restore ex vivo
ardiac muscle contraction in response to -agonist stimu-
ation. It was thought that this restoration of AR signaling
n the heart was primarily due to hemodynamic factors
esulting from unloading of the left ventricle. More recently,
t has been demonstrated that there is significant improve-
ent in AR signaling in both the left ventricle and the
ight ventricle after LVAD support.14 This study suggested
hat restoration of the myocardial AR signaling pathway s
The Journal of Thoracicuring LVAD support is primarily mediated by systemic
actors, such as biochemical milieu, and is not directly
ediated by hemodynamic factors.
The primary objective of the present study was to deter-
ine the role of GRK activity in the restoration of left
entricular AR signaling after LVAD support. We hypoth-
sized that the relative normalization of the neurohormonal
ilieu resulting from mechanical unloading1,23 and signif-
cantly improved cardiac hemodynamics would lead to a
ecrease in GRK2 expression and activity. This would
llow for the restoration of AR density to near normal and
ould enhance coupling through these receptors as a result
f a lower degree of GRK-mediated desensitization.
As others have reported,13,14 we also found that long-
erm LVAD support can restore myocardial AR signaling,
s demonstrated by increasing sarcolemmal membrane AR
ensity to near normal. Basal and -agonist stimulated
denylyl cyclase activity was also restored to normal during
VAD support. The expression and activity of GRK2, the
rimary GRK in the heart, were reduced by nearly 3-fold to
ormal levels in the LVAD group. In addition, there was a
ignificant reduction in left ventricular expression of Gi, the
yclase inhibitory G protein, as a result of LVAD support,
hich likely plays a role in the normalization of adenylyl
yclase activity and improved myocyte contractility.
The critical role of GRK2 as a mediator of cardiac
unction has been well described. Transgenic mice with
ardiac-specific overexpression (3-fold) of GRK2 have se-
erely blunted basal and -agonist–stimulated left ventric-
lar function.15 In contrast, mice with cardiac-specific ex-
ression of a peptide inhibitor of GRK2 have significantly
nhanced basal and agonist-stimulated cardiac contractility
ecause desensitization of myocardial ARs is dimin-
shed.15 -Adrenergic– based gene therapy approaches us-
ng an inhibitor of GRK2 activity have also been successful
n restoring AR signaling in failing cardiac myocytes,27 as
ell as improving cardiac function in animal models of
yocardial infarction and HF.28,29 A recent report demon-
trated that increased cardiac GRK2 levels correlate with
ecreased AR signaling in failing hearts.30 The study also
uggested that increased cardiac GRK2 levels might be
ssociated with poorer cardiac function or clinical signs of
F. Another important finding in this study was the direct
emonstration that cardiac GRK2 levels can be monitored
y measuring peripheral lymphocyte GRK2 expression and
ctivity.30
Our study is the first to demonstrate that myocardial
RK2 expression and activity can be modulated or inhib-
ted in human HF. Long-term LVAD support led to a
ignificant decrease in cardiac GRK2 levels of expression
nd activity compared with medical therapy and resulted in
estoration of left ventricular AR signaling. There was a
ignificant upregulation of AR density, a decrease in Gi
and Cardiovascular Surgery ● Volume 131, Number 5 979
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9
CSPxpression, and an increase in basal and -agonist–stimulated
AMP production. The decrease in cardiac GRK2 levels
ight be due to relative normalization of the neurohormonal
ilieu after the improved hemodynamic status of these
atients with HF who were receiving LVAD support. Mon-
toring peripheral lymphocyte GRK2 levels, which appear
o correlate with cardiac GRK2 activity, after LVAD sup-
ort might provide important additional clinical data in
sing LVADs as a bridge to myocardial recovery in the
etting of chronic HF. Restoration of myocardial AR sig-
aling through inhibition of GRK2 activity in human HF
ight represent a novel therapeutic strategy for this disease.
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